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Abstract
Introduction: There is currently no published data on the effectiveness of DAA treatment for elimination of HCV infection in
HIV-infected populations at a population level. However, a number of relevant studies and initiatives are emerging. This
research aims to report cascade of care data for emerging HCV elimination initiatives and studies that are currently being
evaluated in HIV/HCV co-infected populations in the context of implementation science theory.
Methods: HCV elimination initiatives and studies in HIV co-infected populations that are currently underway were identified.
Context, intervention characteristics and cascade of care data were synthesized in the context of implementation science
frameworks.
Results: Seven HCV elimination initiatives and studies were identified in HIV co-infected populations, mainly operating in
high-income countries. Four were focused mainly on HCV elimination in HIV-infected gay and bisexual men (GBM), and three
included a combination of people who inject drugs (PWID), GBM and other HIV-infected populations. None were evaluating
treatment delivery in incarcerated populations. Overall, HCV RNA was detected in 4894 HIV-infected participants (range
within studies: 297 to 994): 48% of these initiated HCV treatment (range: 21% to 85%; within studies from a period where
DAAs were broadly available the total is 57%, range: 36% to 74%). Among studies with treatment completion data, 96% of
1109 initiating treatment completed treatment (range: 94% to 99%). Among those who could be assessed for sustained viro-
logical response at 12 weeks (SVR12), 1631 of 1757 attained SVR12 (93%, range: 86% to 98%).
Conclusions: Early results from emerging research on HCV elimination in HIV-infected populations suggest that HCV treat-
ment uptake is higher than reported levels prior to DAA treatment availability, but approximately half of patients remain
untreated. These results are among diagnosed populations and additional effort is required to increase diagnosis rates. Among
those who have initiated treatment, completion and SVR rates are promising. More data are required in order to evaluate the
effectiveness of these elimination programmes in the long term, assess which intervention components are effective, and
whether they need to be tailored to particular population groups.
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1 | INTRODUCTION
Over two million people are estimated to be HIV/HCV co-
infected globally [1]. Chronic viral hepatitis accounts for
approximately 10% of mortality among people living with HIV
[2]. Injecting drug use is the major risk factor for HCV acquisi-
tion among those living with HIV, accounting for over 60% of
infections globally, whereas in many high-income countries,
high-risk sexual behaviour among HIV-infected gay and bi-sex-
ual men (GBM), including injecting and non-injecting drug use
to enhance the sexual experience, is a key driver of HCV
transmission [1,3,4]. Incarcerated populations are also at ele-
vated risk of HCV and HIV infection due to incarceration of
people who inject drugs (PWID) [5].
HCV treatment has been transformed through direct-acting
antiviral (DAA) medications that cure >90% of individuals using
tablets over 8 to 12 weeks [6]. Despite modelling studies sug-
gesting that if HCV treatment can be adequately scaled to need,
HCV prevalence and incidence can be reduced [7,8] and opti-
mism that local elimination of HCV might be achieved [9], real-
world scale-up of HCV elimination remains largely hypothetical.
Though the high price of DAAs has hindered scale-up [10],
treatment levels have also been hindered by ineffective strate-
gies to adequately target key populations who would benefit
most from HCV treatment as prevention [11].
The HIV co-infected population are more likely to be engaged
in medical care than the HCV-mono-infected population given
increasingly high levels of HIV ART uptake globally [12].
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Theoretically, this provides an opportunity for broad coverage of
HCV treatment in this population, particularly given that DAA
treatment regimens are similar in co-infected and mono-infected
populations with equivalent treatment outcomes [13,14]. How-
ever, it is important to note that despite increases in ART cover-
age, coverage in the key at-risk populations still lags behind in
some contexts possibly due to lower levels of engagement in
medical care and discriminatory prescribing practices [15,16].
Despite the advantages of DAA therapy, engaging large
numbers of HIV/HCV co-infected people in HCV DAA treat-
ment will likely require tailored strategies for each of the
three key groups at risk of co-infection: PWID, GBM and pris-
oners. A number of key barriers will need to be addressed to
achieve a comprehensive increase in HCV treatment coverage
in these three key populations. Insights from implementation
science suggest that the successful and widespread implemen-
tation of any innovation is complex, even one that is sup-
ported by a high level of evidence [17,18]. This is partially due
to barriers at the level of the individual health professional,
such as lack of knowledge or skill or negative attitudes, but
also involves structural barriers, organizational barriers, peer
group barriers (differences between the local standard of care
and the desired practice) and professional-patient interactions
[19]. In the case of HCV, stigmatization and criminalization of
the major patient groups and frequent incarceration of PWID
add further to the complexity [20,21].
There is currently no published real-world data on the
effectiveness of DAA treatment for elimination of HCV infec-
tion in HIV-infected populations at a population level. How-
ever, a number of relevant studies and initiatives are
emerging. This paper aims to describe and report cascade of
care data for emerging HCV elimination initiatives and studies
that are currently being trialled in HIV/HCV co-infected popu-
lations in the context of implementation science theory.
2 | METHODS
Seven HCV elimination initiatives and studies in HIV co-
infected populations that are currently underway were identi-
fied in six countries. Eligibility criteria for inclusion were either
(a) monitoring an HCV elimination intervention targeted to
HIV-infected populations; or (b) monitoring the effects of
HCV elimination interventions in HIV-infected populations.
Data on context, intervention characteristics, and initiative/
study-level cascade of care were synthesized using conference
abstracts, published manuscripts and personal contact with
the investigators. Data collection tools were informed by rele-
vant constructs from the consolidated framework for imple-
mentation research (CFIR) [17] and the integrated Promoting
Action on Research Implementation in Health Services frame-
work (i-PARIHS; Figure 1) [18]. Cascade of care data from
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Figure 1. Overview of the CFIR and i-PARIHS implementation science frameworks with relevant constructs highlighted. While all constructs
in the two implementation science frameworks are potentially relevant to HCV elimination interventions, the highlighted constructs are par-
ticularly relevant for describing and analysing progress in HCV elimination in HIV-infected populations, both in the initiatives and studies
identified and in the global context.
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initiatives and studies included the number of people with
HCV RNA, the proportion of those with HCV RNA who initi-
ated treatment, the proportion of those who initiated treat-
ment that completed treatment, and the SVR rate. Where
possible the SVR rate was defined as the proportion of those
who were at least 12 weeks past their expected treatment
completion date, who had attained SVR. Data on diagnosis
rates were not generally available at the initiative/study level.
For each country in which initiatives and studies were
included, model-based estimates of the numbers of people liv-
ing with HIV and the proportion diagnosed with HIV were
sourced from peer-reviewed journal manuscripts [22,23],
surveillance reports [24-26], and conference presentations
[27]. Estimates of HCV antibody prevalence among HIV-
infected populations were obtained from cohort studies of
people living with HIV [26,28-30], clinical databases of HIV
patients [27], and country-level HIV/HCV co-infection man-
agement guidelines [31]. The number of people affected by
HCV/HIV co-infection was calculated by applying the HCV
antibody prevalence estimates to the estimates of the num-
bers of people living with HIV. An estimate of the proportion
of those with HIV/HCV co-infection who were diagnosed for
both HIV and HCV was only available for one country, and it
was sourced from a conference presentation [27].
All contributing studies had received ethical approval from
local ethics review boards in their countries.
3 | RESULTS - PROGRESS TOWARD
HCV ELIMINATION IN HIV-INFECTED
POPULATIONS
3.1 | Emerging research
Seven HCV elimination initiatives and/or studies in HIV-
infected populations were identified, mainly in high-income
countries (Australia (n=2), Canada, France, Georgia, the
Netherlands and Switzerland). The broader context in which
an intervention takes place is highlighted by the i-PARIHS
framework (Figure 1). The six countries in which elimination
initiatives or studies were identified all have harm reduction
programmes for PWID, and protection against discrimination
for LGBT populations. [32-33]. However, the coverage of harm
reduction programmes varies substantially between countries.
According to a recent systematic review, needle and syringe
programme coverage was high in Australia and the Nether-
lands (>200 needles/syringes distributed per PWID per year),
moderate in Canada, France and Switzerland (100 to 200 nee-
dles/syringes distributed per PWID per year) and low in Geor-
gia (0 to 50 needles/syringes distributed per PWID per year).
Opioid substitution therapy coverage was high in Australia,
France, the Netherlands and Switzerland (>40 recipients per
100 PWID), moderate in Canada (20 to 40 recipients per 100
PWID), and low in Georgia (0 to 20 recipients per 100 PWID)
Table 1. Country-level context of the identified HCV elimination initiatives and studies in HIV-infected populations
Australia Canada France Georgia Switzerland The Netherlands
Main population groups affected by HIV/HCV co-infection
PWID N Y Y Y Y Ya
GBM Y Y Y Y Y Y
Prisoners N Y Y Y Y N
Other N Yb N Y N N
National/regional HCV elimination strategy Y N Y Y N Y
Availability of subsidized DAAs
Unrestricted in HIV-coinfected population (year) Y (2016) Y (2014/2017)c Y (2017) Y (2015) Y (2017) Y (2015)
Unrestricted for all chronic HCV patients (year)d Y (2016) Ne Y (2017) Y (2015) N Y (2015)
Prescriber types
Specialists Y Y Y Y Y Y
Primary care Y Y/Nf N Ng N N
Legal constraints for key populations
Harm reduction programmes for drug use Y Y Y Y Y Y
Protection against discrimination for LGBT populations Y Y Y Y Y Y
aIn the Netherlands, HCV/HIV coinfection is mainly observed in former PWID and GBM. Recent transmission has been observed only among
GBM. Similar to the situation in other high-income countries, HCV transmission among GBM is thought to be driven partially by sexual transmis-
sion and partially by injecting and non-injecting drug use to enhance the sexual experience.
bIndigenous populations (mainly through injecting drug use).
cSimeprevir and sofosbuvir were unrestricted in Quebec for HCV mono-infected patients since 2014. Although HIV infection was a listed restric-
tion, co-infected patients were usually granted access on a case by case basis through the “patient d’exception” process; Ledipasvir and ombitasvir/
paritaprevir/ritonavir; dasabuvir were unrestricted in Quebec from 2016 and velpatasvir from 2017; and the majority of other Canadian provinces
since March 2017 [34].
dGenerally excluding those who are incarcerated.
eNot currently available but this is expected to change in 2018/9 in the majority of Canadian provinces.
fPrimary care practitioners can prescribe HCV treatment in some provinces but not others [34].
gA pilot programme is currently underway to evaluate HCV treatment in primary care, which is expected to lead to all primary care providers
being allowed to prescribe HCV treatment.
Sacks-Davis R et al. Journal of the International AIDS Society 2018, 21(S2):e25051
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25051/full | https://doi.org/10.1002/jia2.25051
28
[32]. HCV elimination strategies operating at the regional or
country level were in place in Australia, France, Georgia and
the Netherlands (Table 1).
In addition to the broad context, another key aspect is the
characteristics of the patient or target group of the interven-
tion (Figure 1). The main population groups affected by HIV/
HCV co-infection in the countries in which elimination initia-
tives were identified included PWID, GBM and incarcerated
populations. However, the majority of the elimination efforts
were targeted elimination efforts in GBM. The two Australian
initiatives (CEASE and Co-EC) operate primarily in cities
where GBM account for approximately 85% of HIV/HCV co-
infection cases; in Amsterdam, ongoing transmission of HCV
infection among HIV-infected populations is only among GBM;
and in Switzerland, the Swiss HCVree Trial is a clinic trial with
MSM as an eligibility criterion. Notably, the HCVree study is
nested in the Swiss HIV Cohort Study which includes PWID,
GBM and other HIV-infected participants, and because treat-
ment data are not yet available for HCVree, the cascade of
care data presented here are from the Swiss HIV Cohort
Study. The nationwide HCV elimination programme in Georgia
provides HCV treatment at harm reduction sites for PWID,
HIV centres, and prisons. In Canada and France, there are no
specific programmes targeting HIV-infected populations but
the effects of general HCV elimination programmes are being
evaluated in the HIV-infected community. France’s national
strategy for HCV elimination includes targeted programmes
for PWID. Broad availability of DAAs is the only nation-wide
elimination initiative in Canada but there are other HCV elimi-
nation initiatives in Canada that are targeted to specific sub-
populations and geographic areas. The cohort studies and
databases being used to evaluate the effects of HCV elimina-
tion programmes in Canada, France and Georgia include
diverse HIV-infected populations including active PWID and
GBM. (Table 2).
One of the characteristics highlighted in the CFIR is the
complexity of the intervention (Figure 1). HCV elimination in
HIV-infected populations is complex. All of the initiatives and
studies include broad access to DAAs and most include addi-
tional components, including screening and testing compo-
nents, treatment access components, training of health
professionals, media campaigns and risk reduction compo-
nents. Screening and testing interventions include nurse sup-
ported programmes to identify patients for HCV antibody
testing, community-based rapid diagnostics and home-based
dried blood spot testing, and study or community-based rein-
fection monitoring. Treatment access interventions include a
case management programme for PWID and marginalized
people, broadened prescriber base, treatment provision at
harm reduction sites, treatment provision in prison, nurse-led
primary healthcare based models of care, and community
and cohort-study based test and treat models. Risk reduction
components include harm reduction, healthcare-based infec-
tion control, behavioural interventions and personalized
online tools for those at risk of reinfection. Of the five broad
groups of intervention (screening/testing, treatment access,
training of health professionals, media campaigns and risk
reduction interventions), MC Free and Georgia’s nationwide
HCV elimination programme involve components from all five
groups, Co-EC Australia involves components from four
groups, CEASE Australia involves components from three
groups, the National Plan for HCV Elimination and the Swiss
HCVree trial include components from two groups. Although
there are no targeted national elimination interventions in
Canada, regional interventions such as the Targeted Disease
EliminationTM programme in British Columbia [35] and a pilot
project in Big River First Nation, Saskatchewan are evaluat-
ing eliminating HCV at the community level. Some of the
studies and initiatives include multiple components within a
group (Table 2).
The ability to trial the intervention at a small-scale is also
highlighted in CFIR (Figure 1). In the seven initiatives and
studies identified, cohort studies, health information systems
and surveillance systems are being used to evaluate HCV
elimination interventions in people living with HIV (Table 2).
None of the evaluation methods include traditional control
groups. However the CCC (Canada) is using quasi-experimen-
tal designs to (i) evaluate treatment uptake through natural
variations in DAA reimbursement policies across Canada and
(ii) pilot elimination interventions at the clinic level, comparing
intervention sites with matched control sites within the CCC.
Similarly, several of the other studies and initiatives are using
nationwide databases and/or cohorts to compare regions/sites
with interventions to other regions.
The cost and available resources for implementing an inter-
vention are highlighted in CFIR and i-PAHRIS (Figure 1). With
the exception of the Swiss HCVree Trial, where drugs are pro-
vided by industry, governments and health insurance provide
funding for subsidized DAAs in all of the other HCV elimina-
tion initiatives and studies. However, with the exception of the
government-funded National Plan for HCV elimination in
France and the nationwide HCV elimination programme in
Georgia which is partially industry-funded and partially funded
by the US CDC among others, additional components of the
elimination interventions identified were mainly funded by
industry through investigator-initiated research. These compo-
nents include treatment access interventions, screening/test-
ing, education initiatives for health professionals, media
campaigns and risk reduction interventions.
3.2 | Country-level burden of HIV/HCV
co-infection and diagnosis
Model-based estimates of the number of people living with
HIV were available for all six countries in which the identified
HCV elimination initiatives and studies were based. These ran-
ged from 9600 in Georgia to 149,900 in France. The percent
of HIV-infected participants with HCV antibodies ranged from
12% in the Netherlands to 40% in Georgia. The number of
people living with HIV and HCV antibodies ranged from 2600
in Switzerland to 36,400 in France. The percent of HIV-
infected individuals who were HIV diagnosed ranged from
42% in Georgia to 89% in Australia (Table 3). An estimate of
the percent of co-infected individuals who were diagnosed for
both HIV and HCV was reported in a conference presentation
for Georgia (33%) [27], but was not available for any of the
other countries. According to systematic reviews and mod-
elling studies, the estimated proportion of people living with
HCV (including those with HCV monoinfection) who were
diagnosed prior to DAA availability was 37% (Switzerland),
57% (France), 61% (the Netherlands), 70% (Canada), 75%
(Australia) [36-39]. However, in some countries these
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Table 2. Intervention characteristics of seven key studies targeting HCV elimination in HIV/HCV co-infected populations
Name (location) Scope of intervention Intervention components
Who covers the cost of
the intervention
Evaluation method in
HIV-infected
populations
(Canada) Nation-wide Broad access to DAAs;
additional clinic-level, province-
level, and community-level
interventions
Government/health
insurancea
Canadian co-infection
cohort [40]
co-EC (Melbourne,
Australia)
Three high HIV caseload
primary healthcare
clinics, the largest
metropolitan sexual
health centre, and the
two largest hospitals for
care of people living with
HIV, accounting for over
75% of people living with
HIV in Victoria
Broad access to DAAs and
broadened prescriber base;
nurse supported programmes to
identify patients for HCV
testing, and support for GPs to
increase testing and treatment;
posters displayed in
participating clinics promoting
HCV testing to patients;
nurse-led model of care in
primary healthcare to increase
access to DAAs;
training programmes for nurses
and physicians
DAA therapy is
government subsidized;
practice nurses are
funded by industry
through investigator
initiated research
An integrated HCV/HIV
clinical and
behavioural
surveillance system
monitors the impact
of the programme at
the local and
statewide level
CEASE
(predominantly
Sydney, Australia)
Nation-wide observational
study of HCV viraemia
among HIV-infected
population, with an
implementation project
predominantly operating
in Sydney
Broad access to DAAs and
broadened prescriber base;
HCV Education for HIV
prescribers;
recurrent viraemia: monitoring
of a cohort of high-risk inner
city patients for reinfection
DAA therapy is
government subsidized;
other intervention
components funded by
industry through
investigator initiated
research
Data assessed at three
cross-sectional visits;
at enrolment (2014
to 2016), follow up 1
(2017 to 2018) and
follow up 2 (2019 to
2020); data include
HCV viraemic
prevalence through
DBS, behavioural risk
and fibrosis
assessment
MC FREE
(Amsterdam MSM
HCV Free,
Amsterdam, the
Netherlands)
City-wide Broad access to DAAs;
home-based HCV RNA dried
blood spot testing service
(subscription-based);
online tools including
information and personal advice
on testing and risk reduction
strategies, and test results
delivered online;
motivational interviewing and
intensification of partner
notification;
online and offline media
campaigns aimed at increasing
HCV awareness;
interventions aimed at
professionals;
behavioural interventions by
trained HIV nurses
DAA Treatment is
government subsidized;
home-based testing and
online/ offline strategies
are supported by
industry through
investigator initiated
research
Through the National
HIV Monitoring
Foundation and the
MOSAIC study, the
different
interventions will be
evaluated according
to predefined
criteria/ deliverables
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Table 2. (Continued)
Name (location) Scope of intervention Intervention components
Who covers the cost of
the intervention
Evaluation method in
HIV-infected
populations
National Plan for
HCV Elimination
(France)
Nation-wide, community-
based intervention
Broad access to DAAs;
community-based test and treat
model involving implementation
of rapid diagnostics at the
community level;
educators and social workers
who link PWID / marginalized
people to healthcare centres,
through a case management
(parcours) programme
Government/health
insurance
Several cohorts of HIV-
infected patients and
HIV/HCV co-infected
patients in addition to
national surveillance
systems
National HCV
elimination
programme
(Georgia)
Nation-wide multi-
component programme
Broad access to treatment and
increased access to treatment
through primary care, harm
reduction sites, HIV centres and
prisonsb;
advocacy, awareness and
education;
harm reduction among PWID,
blood safety and infection
control in traditional and non-
traditional healthcare settings;
national HCV screening
Laboratory diagnostics capacity
building;
surveillance
Gilead and the CDC among
others
Georgian National AIDS
health information
system (AIDS HIS, a
secure web-based
system connecting all
HIV care providers
countrywide)
The Swiss HCVree
Trial (Switzerland)
Research study-based
elimination effort among
HIV/HCV co-infected
MSM, operating
nationwide
Cohort study based test and treat
model; delivery of Elbasvir/
Grazoprevir treatment to
patients infected with
genotypes 1 and 4 through
clinical trial (Swiss HCVree
Trial); behavioural intervention
delivered to patients reporting
inconsistent condom use with
occasional partners; the
remaining patients received
standard of care and written
and oral information on
prevention of HCV reinfection.
Investigator initiated trial
nested in the Swiss HIV
Cohort Study (SHCS);
SHCS mainly funded by
the Swiss National
Science Foundation,
HCVree mainly funded
by industry
The Swiss HCVree
Trial: all study
participants tested
for HCV RNA at
beginning and end of
the HCVree trial,
change in risk
behaviour is
evaluated, see
ClinicalTrials.gov
NCT02785666;
effects on HCV
incidence within HIV-
infected populations
evaluated using the
Swiss HIV Cohort
Study
aAlthough all Canadian citizens and permanent residents have insurance coverage for in-hospital and physician services, medication coverage var-
ies across the 10 provinces and 3 territories, with a mix of both public and private sources of insurance depending on individual characteristics.
For example, people on social assistance receive public coverage for medications with no or minimal co-payments and Indigenous people receive
medication coverage from the First Nations and Inuit Health Branch (FNIHB).
bProvision of HCV treatment through primary care and harm reduction sites is currently being piloted and will be implemented nationwide in the
future.
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diagnosis rates may be quite different in the HIV-infected
population.
3.3 | Initiative-level partial cascade of care
Overall, HCV RNA was detected in 4894 HIV-infected partici-
pants across the seven studies and initiatives (range within
studies: 297 to 994). Of these 2338 initiated HCV treatment
(48%; range: 21% to 85%). Among studies with treatment
completion data, 1061 of 1109 initiating treatment (96%,
range: 94% to 99%), completed treatment. Of those who were
treated with DAAs and could be assessed for SVR12, 1631 of
1757 attained SVR12 (93%, range: 86% to 98%). Of the seven
studies and initiatives, four reported cascade of care data
from a period where DAAs were broadly available (CEASE
and Co-EC - Australia, ATHENA - The Netherlands and AIDS
HIS-Georgia), and three included data from prior to DAAs
becoming broadly available (CCCS - Canada, SHCS - Switzer-
land, and HEPAVIH- France). Four initiatives/studies included
a considerable proportion of PWID in addition to GBM and
other patient groups (CCCS, AIDS HIS, HEPAVIH and SHCS),
and three were composed mainly of GBM and former PWID
(CEASE, Co-EC and ATHENA). In studies and initiatives with
cascade of care data from a period where DAAs were broadly
available, 1398 of 2460 (57%, range: 36% to 74%) initiated
HCV treatment, 160 of 169 (95%: data from one study only)
completed HCV treatment, and 1042 of 1110 (94%, range:
88% to 98%) attained SVR12. In studies and initiatives that
include a considerable proportion of current PWID, 1271 of
3349 (38%, range: 21% to 85%) initiated treatment, 901 of
940 (96%: range: 94% to 99%), completed HCV treatment,
and 885 of 978 (90%, range: 86% to 96%) attained SVR12;
however, two of these studies and initiatives include data from
prior to DAAs becoming broadly available (Table 4 and Fig-
ure 2). These data include diagnosed patients, who are in care
(France, the Netherlands, Sydney), were in care previously
(Melbourne, Georgia) and/or are enrolled in a cohort study
(Canada, France, the Netherlands and Switzerland).
4 | DISCUSSION
Early results were synthesized from seven HCV elimination
initiatives and studies in HIV-infected populations. These
results demonstrate increased linkage to HCV care, successful
retention in care, and high cure rates among those diagnosed
with HCV/HIV co-infection. However, these are early data and
the majority of initiatives and studies identified were in high-
income countries with relatively low levels of criminalization
of risk behaviours and discrimination and stigma of PWID and
GBM. Furthermore, the majority of initiatives and studies
identified were either primarily treating GBM and/or former
PWID or include data from prior to broad DAA availability.
None of the studies operate in incarcerated populations and
treatment in this context may be more challenging. More data
will be required to evaluate the effects of treatment scale-up
on HCV prevalence and incidence, and confirm that these high
rates of linkage and retention in care can be replicated in
PWID, incarcerated populations, and in countries with greater
levels of criminalization of risk behaviours and discrimination
and stigma of the groups at risk. Different strategies may be
required for linkage and retention in care in different
populations.
Overall, approximately 50% of HCV diagnosed individuals in
the seven initiatives and studies were linked to HCV treat-
ment. This represents a substantially higher treatment uptake
than prior to DAA therapies becoming available. In the Swiss
HIV cohorts, treatment uptake increased fourfold after the
introduction of second-generation DAAs [42]. In Georgia,
approximately 100 HCV/HIV co-infected people were treated
per year in the three and a half years prior to DAA availability,
compared to approximately 265 treatments/year in the first
15 months of the nationwide HCV elimination programme
[27]. In the CCC (Canada), treatment uptake increased from 8
per 100 person years to 28 per 100 person years after the
introduction of DAA therapies. [43]. This is consistent with
increases in treatment uptake following the introduction of
DAA therapies in predominantly HCV-monoinfected popula-
tions [44]. However, it is not clear that these increases in
treatment rates will be sustained. In the Netherlands, treat-
ment numbers increased substantially from November 2015
when DAA therapy became available until July 2016 (on aver-
age, >150 treatments/quarter) but then returned to pre-DAA
levels (<50 treatments/quarter) [45]. Moreover, although sub-
stantial increases in treatment uptake were observed after
the introduction of DAA therapy, treatment uptake varied sub-
stantially between studies (21% to 91%). This is partially due
to variations in when broad access to DAA therapy was
attained: in Canada, France, and Switzerland, although DAA
therapies were available to selected subgroups earlier, broad
access to DAA therapies was only attained in 2017 and cas-
cade of care data was either not yet available or included data
Table 3. Country-level burden of HIV/HCV co-infection and diagnosis
Australia Canada France Georgia Switzerland The Netherlands
Estimated number of people living with HIV 26,400 [24] 65,000 [25] 149,900 [22] 9600 [27] 15,200 [23] 22,900 [26, 41]
Estimated % with HCV antibodies 13 [28] 20 to 30 [31] 24 [29] 40 17 [30] 12 [26]
Estimated number with HCV antibodies 3500 16,300 36,400 3900 2600 2700
Estimated % of those living with
HIV who are HIV diagnosed
89 [24, 28] 80 [25] 81 [22] 42 [27] 81 [23] 89 [26, 41]
All numbers are rounded to the nearest 100 and percentages are rounded to the nearest percent. Estimated numbers with HCV antibodies are
calculated by applying the estimated % with HCV antibodies to the estimated number of people living with HIV. Percent HIV diagnosed is among
all HIV-infected people.
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from before broad access was attained. Treatment rates may
have increased since DAAs became broadly available.
However, even in initiatives and studies that attained broad
access to DAA therapies earlier, treatment uptake ranged
from 36% in Georgia to 75% in the Netherlands indicating
that there are significant barriers to care other than simply
access to DAA therapy, including provider-level, patient-level
and structural barriers ([19-21], Table 5). Overall, more than
half of diagnosed HIV/HCV co-infected individuals had not
received treatment. While the data included only reflect a
short timeframe after the introduction of DAAs, this suggests
that substantial effort is still required to achieve HCV elimina-
tion in HIV-infected populations. In order to overcome the
potential barriers to HCV elimination, it is likely that complex
interventions will be required. These are likely to include
interventions related to linkage and retention in care, diagno-
sis and screening, training of health professionals, risk reduc-
tion and identification and treatment of reinfection cases.
Notably, currently the majority of intervention components in
the identified studies and initiatives other than DAA therapy
are funded by industry through investigator-initiated research.
In order to attain HCV elimination globally, sustainable financ-
ing structures will be required to monitor the effectiveness of
HCV elimination efforts and for widespread implementation of
interventions that are proven to be effective.
All treatment linkage data reflect HIV and HCV diagnosed
populations. Population-wide proportions of those diagnosed
with HIV/HCV co-infection who have received treatment are
likely to be lower than those presented here. HCV diagnosis
rates among HIV-infected populations are not currently well
understood and additional research is required to estimate
Table 4. Partial cascade of care in the HCV elimination interventions/studies identified in HIV-infected populations
CEASE
Australia
Co-EC
Australia
CCC
Canada
HEPAVIH
France
AIDS HIS
Georgiaa
SHCSb
Switzerland
ATHENAc
The Netherlands
Number HCV RNA positive 297d 305e 994f 564 915 876 943g
Number initiated HCV treatment (%)h 196 (66) 169 (55) 278 (28) 482 (85)i 331 (36) 180 (21) 702 (74)
Number completed HCV treatment (%)j - 160 (95) 271 (97)k 451 (94) - 179 (99) -
Number attained SVR12 (%) 15 (88)l 133 (89)m 240 (86)n 176 (93)o 296 (89) 173 (96) 598 (98)p
CEASE, Control and Elimination within AuStralia of HEpatitis C from people living with HIV; co-EC Study, Eliminating HCV/HIV co-infection; CCC,
Canadian Co-infection Cohort; HEPAVIH, the French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPA-
VIH); AIDS HIS, AIDS health infection system; SHCS, Swiss HIV Cohort Study; ATHENA, AIDS Therapy Evaluation in the Netherlands (ATHENA)
cohort.
aData from the Georgian National AIDS health information system (a secure web-based system connecting all HIV care providers countrywide),
June 2015 to August 2016. DAAs were broadly available.
bCascade of care in the Swiss HIV Cohort Study because cascade of care data are not yet available for the Swiss HCVree Trial. Data are from
2014 to 2015. Second-generation DAAs were available but restricted by liver disease stage [42].
cCascade of care from the ATHENA cohort of people diagnosed with HIV in the Netherlands from a period where DAAs were broadly available
but prior to MC Free, Amsterdam [45]. A cascade of care at the two largest HIV clinics in Amsterdam (a subset of the ATHENA cohort) is avail-
able for the same period [46].
d2014 to 2016 [47].
eThese are patients who have been tested for HCV in the past but may not currently be in HCV care. Among those who have been tested for
HCV within the study period (n=194), the treatment uptake is 87%.
fAs of 21 November 2013 (Health Canada’s approval of second-generation DAAs), cohort participants who were eligible to initiate DAAs.
gIncludes those who have tested HCV RNA positive, were treated with DAAs, have never been treated, or were treated with interferon-based
therapies and failed treatment but have not yet been retreated [45].
hOf those HCV RNA positive.
iIncludes initiations with interferon-based therapies during a period when DAAs were available in France but restricted [48].
jOf those initiating HCV treatment.
kData collected up to December 2016.
lUp to end 2015 (17 had initiated treatment).
mOf those who are 12 weeks past the date of planned treatment completion. 136 of these were tested for HCV RNA at 12 weeks after treat-
ment, and of those the SVR rate was 98%. It is likely that more participants will be tested for HCV RNA at their next HIV clinic visit.
nIncludes DAA regimens including interferon, data collected up to July 2017 [43].
oOf those initiating DAA therapy prior to February (24 week therapy)/May 2015 (12 week therapy) [49].
pOf those who were assessed for SVR.
Figure 2. Partial cascade of care data from seven initiatives and
studies implementing and evaluating HCV elimination interventions
in HIV-infected populations. Percent of HCV RNA positive partici-
pants in care or enrolled in cohort studies initiating treatment, per-
cent of those initiating treatment who have completed treatment,
and percent of those who can be assessed for SVR12 who attained
SVR12.
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these. Two of the initiatives and studies identified included
interventions to increase HCV diagnosis in HIV diagnosed
populations using community-based rapid diagnostics and
home-based dried blood spot testing. Dried blood spot testing
administered by professionals has previously been found to
increase HCV testing uptake in populations at high risk of
HCV monoinfection [63]. In Georgia, where the rate of HIV
diagnosis is relatively low (approximately 40%), efforts are
being made to increase diagnosis through integration of HIV,
HCV and TB testing services [64].
Table 5. Barriers and enablers of HCV elimination in HIV-infected populations: list structure based on the CFIR and i-PARIHS
frameworks
Intervention
Strength of evidence High level of evidence that DAAs are efficacious and tolerable in HIV-coinfected individuals [13], model-based
evidence of the effectiveness of treatment as prevention [7,8].
Complexity Complex intervention targeting populations rather than individuals, and involving case finding, engagement and
retention in care, follow-up after successful treatment, and potential re-treatment following re-infection.
Adaptability Case finding strategies and models of HCV care are adaptable [50,51].
Trialability Small-scale trials are challenging because of the interlinked nature of the transmission networks. In many contexts
HCV elimination will only be testable through before and after studies of population-wide interventions.
Cost Initially extremely costly; however, some countries have negotiated better rates or early introduction of generics
and prices of DAAs are evolving rapidly [10,52].
Source Targets have been set by the WHO [9].
Relative advantage In settings where resources are limited relative to the cost of DAAs, treatment of those with advanced liver
disease has been prioritized over those at risk of transmission [52].
Recipients of the intervention
Healthcare professionals Negative attitudes of healthcare providers toward risk groups have been documented in some contexts, with
consequences for quality of care [16,53].
Possible low levels of knowledge of HCV among primary care practitioners managing HIV patients [54]
Patients Linkage to healthcare and treatment readiness in key population groups, including possible mistrust of healthcare
providers among key risk groups [20]
Transience of key populations, particularly PWID, including frequent short-term incarceration [20,55]
Priority of HCV care in the context of comorbidities and socio-economic disadvantage [20]
Relationships between
healthcare professionals
and patients
Communication difficulties between patients and specialists [20]
Context
Criminalization,
discrimination and stigma
of key populations
Criminalization of same-sex sexual acts in 75 countries [33]. High or medium levels of discrimination against gay
and bisexual men limit access to HIV-care in low and middle-income countries in all global regions [56], limiting
access to care for HCV in HIV health services.
Criminalization of drugs is widespread, with decriminalization of some aspects of drug use only in relatively few
countries, approximately 25 to 30 worldwide. There is some evidence that criminalization of drugs and stigma
against PWID in healthcare settings negatively impact on HIV prevention and healthcare [53,57,58], and may
impact negatively on HCV treatment among HIV-infected populations.
Incarceration of
key populations
Incarceration of PWID and less commonly of GBM poses challenges not only for HIV and HCV-prevention, but
also delivery of HCV treatment [59]. While prisons may potentially provide opportunities for HCV treatment,
there are also potential challenges to providing continuity of care in the context of prison transfers and short
sentences, lack of family support, high levels of stress, unpleasant healthcare context and stigmatization by
other inmates and custodial staff [55]. In addition, high rates of reinfection have been observed in the prison
setting, highlighting the importance of offering other harm reduction interventions such as OST alongside HCV
treatment [60,61].
Health systems and
regulatory frameworks
Prescriber-type restrictions for HCV treatment [62], and lack of access to transient elastography [54] may impact
on access to care [20]
Resourcing Resourcing limitations within countries are a function of drug prices (which vary substantially between countries),
epidemic size and available resources. In addition to funding of drugs, screening, health-systems and risk
reduction intervention costs also need to be considered.
Formal endorsement at
a country or regional level
While HCV elimination is recommended by the WHO, formal endorsement at a country or regional level varies
between countries.
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It is likely that appropriate strategies to improve linkage to
care and maintenance in care will differ by population group
regardless of whether they are HIV/HCV co-infected or HCV
monoinfected. For PWID, prior to the introduction of DAA ther-
apy, a meta-analysis of determinants of HCV treatment comple-
tion and efficacy in drug users found that addiction treatment
and support services during HCV therapy predicted treatment
completion, and the involvement of a multidisciplinary team pre-
dicted SVR [51]. A subsequent meta-analysis that included stud-
ies of drug-using and other populations found that coordinated
mental health, substance use and HCV treatment services had a
modest effect on treatment completion and SVR but not on
treatment uptake. The level of evidence was rated as very low
on the GRADE scale although that is partially due to the difficul-
ties of conducting blinded randomized controlled trials of these
interventions. The same meta-analysis failed to find any effect of
directly observed therapy on SVR [50]. Since the introduction of
DAAs, conference abstracts describing a range of models of
care for PWID including directly observed therapy [65,66],
addiction treatment and support services during HCV therapy
[67,68], support groups [65], integration of HCV treatment
clinic and harm reduction services [69], community-based clinic
conducting outreach at rehab clinics [70] have all reported high
levels of SVR in PWID with HCV mono-infection.
Four of the HCV elimination initiatives identified in this study
are implementing models of care targeting GBM. These involve
integrating HCV treatment with HIV care, and targeted risk
reduction strategies. Prevention of reinfection was highlighted
as an important component of HCV elimination efforts in HIV-
infected GBM in a mathematical model based on data from the
Swiss Cohort study. In light of empirical evidence of increases in
HCV-related risk behaviours in GBM being enrolled in the Swiss
Cohort Study, the model suggested that if the trend toward
increasing risk behaviours persist, high rates of reinfection will
mean that even very high treatment rates will not result in reduc-
tions in HCV incidence unless treatment is combined with beha-
vioural interventions to reduce risk behaviours after treatment
[71]. The HCVree study includes an RCT trialling a behavioural
intervention to prevent reinfection. Results are not yet available.
Prisoners are another complex population likely to require
targeted approaches for HCV elimination. More research is
required to understand strategies for linkage to care in this
context. In addition, indigenous peoples, heterosexuals infected
with HIV, and migrants from high prevalence HIV and HCV
countries are other groups that may also require targeted
approaches for linkage to care and maintenance in care. Fur-
ther research is also required to understand the impact on
HCV elimination strategies in HIV-infected populations of
reinfection following successful HCV treatment [72,73], trans-
mission of HCV between HIV infected and uninfected popula-
tions [74] and migration- and travel-related transmission of
HCV between countries [75]. Furthermore, randomized con-
trolled trials are needed to evaluate the efficacy of strategies
to enhance diagnosis, linkage to care and maintenance in care,
and risk reduction where feasible and ethical.
This study has a number of limitations. HCV elimination ini-
tiatives and studies in HIV-infected populations were not iden-
tified through a systematic search and the list presented here
is not exhaustive. As previously indicated data on treatment
linkage were all early data and represent different stages of
DAA treatment availability.
Early data from the DAA era suggest that HCV treatment
uptake has increased in HIV-infected populations compared to
previous levels, but there is still considerable work to do on the
pathway to HCV elimination in this population. This includes
efforts to quantify the numbers of undiagnosed infections, and
increase diagnosis rates and linkage to care. It is likely that different
strategies will be required for different populations including PWID,
GBM and prisoners among others. Among those who have been
treated with DAAs, treatment completion and treatment success
has been consistently high across a variety of settings.
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